Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine (FAKHRAVAC®) in healthy adults aged 18–55 years: Randomized, double-blind, placebo-controlled, phase I clinical trial...

por Ansarifar, Akram, Farahani, Ramin Hamidi, Rahjerdi, Ahmad Karimi, Ahi, Mohammadreza, Sheidaei, Ali, Gohari, Kimiya, Rahimi, Zahra, Gholami, Fatemeh, Basiri, Pouria, Moradi, Milad, Jahangiri, Arash, Naderi, Kosar, Ghasemi, Soheil, Khatami, Pezhman, Honari, Mohsen, Khodaverdloo, Samane, Shooshtari, Mohammad, Azin, Hajar Mehr, Moradi, Sohrab, Shafaghi, Batool, Allahyari, Hossein, Monazah, Arina, Poor, Ali Khodaei, Bakhshande, Hooman, Taghva, Zahra, Nia, Mohammad Karimi, Dodaran, Masoud Solaymani, Foroughizadeh, Mohsen
Publicado 2023

Phase II randomized, double blind, placebo controlled, clinical trial of safety and immunogenicity of an inactivated SARS-CoV-2 vaccine FAKHRAVAC in adults aged 18–70 years

por Gholami, Fatemeh, Hamidi Farahani, Ramin, Karimi Rahjerdi, Ahmad, Ahi, Mohammadreza, Sheidaei, Ali, Gohari, Kimiya, Rahimi, Zahra, Ansarifar, Akram, Basiri, Pouria, Moradi, Milad, Jahangiri, Arash, Naderi, Kosar, Ghasemi, Soheil, Khatami, Pezhman, Honari, Mohsen, Khodaverdloo, Samane, Shooshtari, Mohammad, Mehr Azin, Hajar, Moradi, Sohrab, Shafaghi, Batool, Allahyari, Hossein, Monazah, Arina, Khodaei Poor, Ali, Taghva, Zahra, Bakhshande, Hooman, Karimi Nia, Mohammad, Solaymani Dodaran, Masoud, Forooghizade, Mohsen
Publicado 2023